As filed with the Securities and Exchange Commission on June 28, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITI ...

FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ For the month of June 2023 Commission File Number: 001-38757 TAKEDA ...

Better Health, Brighter Ful Notice of Convocation of the 147th Ordinary General Meeting of Shareholders Date: June 28, 2023 (Wednesday), 10:00 a.m. Venue: Imperial Hotel, Osaka 3rd Floor | Contents | | --- | | Notice of Convocation of the 147th Ordinary General Meeting of Shareholders | | Guidance Notes on the Exercise of Voting Rights via Electronic | | Means (e.g., the Internet, etc.) . | | Internet live stream and the advance questions . | | Reference Document for the General Meeting of Shareholders | | ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q4 2022 Results Conference Call May 11, 2023 6:00 AM ET Company Participants Christopher O’Reilly - Global Head of IR & Global Finance Christophe Weber - President, CEO & Representative Director Andrew Plump - President of Research & Development and Representative Director Constantine Saroukos - CFO & Representative Director Julie Kim - President of the U.S. Business Unit & U.S. Country Head Giles Platford - President of the Plasma-Derived Therapies Business ...

Table of Contents FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the reg ...

| --- | --- | --- | --- | --- | --- | |--------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | TSE: 4502 | | | | | | | | | | | | | | | | | | | | | | | | | | | | Better health for people, | | | | | | | Brighter future for the world | | | | | | | FY2022 Q3 Earnings Announcement February 2 nd , 2023 | | | | | | The companies in which Takeda directly and indirectly owns investments are separate entities. In this presentation, "Takeda" is sometimes used f ...

Financial Data and Key Metrics Changes - Core revenue for Q3 year-to-date was almost JPY3.1 trillion, reflecting a growth of 4.5% at constant exchange rates [3][24] - Reported revenue growth was 13.9%, with core operating profit growing 9.7% at constant exchange rates to JPY954.7 billion, resulting in a core operating profit margin of 31.1%, an increase of 1.5 percentage points year-over-year [22][24] - Core EPS growth was 17.1% at constant exchange rates, with actual core revenue growth close to 20% and core EPS growth of 37% due to favorable foreign exchange [24][27] Business Line Data and Key Metrics Changes - Growth and Launch products generated approximately JPY1.2 trillion, representing 39% of total revenue and growing at 20% year-to-date at constant exchange rates [25][47] - Neuroscience segment grew by 10%, driven by VYVANSE and TRINTELLIX, while the other segment declined due to regional loss of exclusivities in Japan and low market demand for COVID-19 vaccines [26][88] - PDT Immunology showed strong growth of 18%, including 19% growth in immunoglobulin and 20% growth in albumin, reflecting strong demand [50] Market Data and Key Metrics Changes - The U.S. filing for QDENGA received priority review, and LIVTENCITY showed durable antiviral efficacy in hematopoietic stem cell transplant patients [13][14] - The market for NUVAXOVID in Japan is experiencing lower demand than expected due to the current vaccination situation and prevalence of Omicron [26] Company Strategy and Development Direction - The company aims to create a diverse, equitable, and inclusive working environment, which has been critical in maintaining and developing talent [8] - Strategic investments are being made in long-term growth, including the acquisition of TYK2 inhibitors from Nimbus Therapeutics, which aligns with the company's strategy [10][37] - The company is focused on delivering sustainable growth and value to shareholders, with strong momentum from its commercial portfolio [29] Management's Comments on Operating Environment and Future Outlook - Management is tracking towards the high end of guidance for low single-digit core revenue growth and high single-digit core operating profit and core EPS growth on a constant exchange rate basis [9][23] - The company remains optimistic about its growth outlook, driven by the performance of its Growth and Launch products despite the loss of exclusivity for VELCADE [11][29] Other Important Information - The net debt balance improved from 2.8x to 2.5x, indicating steady deleveraging progress [27][69] - The company plans to maintain its capital allocation policy focused on investing for growth while ensuring competitive shareholder returns [66][69] Q&A Session All Questions and Answers Question: Gross profit margins on a quarter-to-quarter basis - Management noted that gross profit margin improved year-to-date, with a 0.5% increase on an actual basis and 0.1% on a constant exchange basis [56] Question: Market dynamics and pricing for PDT business - Management indicated that PDT growth is driven by volume and demand rather than price, with a slight reduction in donor compensation [90] Question: Concerns about achieving full-year core profit forecast - Management expressed confidence in achieving the full-year forecast of JPY1.18 trillion core operating profit, despite higher R&D and SG&A expenses in Q3 [81][82] Question: Expectations for dividend increases - Management stated that while there is a heightened expectation for increased dividends, they are focused on maintaining their capital allocation policy and will consider updates in the future [82]

41st Annual J.P. Morgan Healthcare Conference Christophe Weber President & CEO January 9th, 2023 Important Notice The companies in which Takeda directly and indirectly owns investments are separate entities. In this presentation, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words "we", "us" and "our" are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful ...

| --- | --- | --- | --- | |----------------------------------------------------------|-------|-------|-------| | | | | | | TSE: 4502 | | | | | | | | | | | | | | | | | | | | Better health for people, Brighter future for the world | | | | | | | | | | FY2022 Q2 Earnings Announcement October 27 th , 2022 | | | | IMPORTANT NOTICE For the purposes of this notice, "presentation" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by ...

Table of Contents FORM 6-K Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of November 2022 ________________________________________ TAKEDA PHARMACEUTIC ...